SynAct Pharma AB insider transactionsStockholm
LEI 549300RRYIEFEQ72N546 · XSTO · SE · Business ID 559058-4826
12-month buy/sell summary
SEK 532,364.22 boughtSEK 8,900,000.00 sold
Open-market buys: 8Sales: 2Share awards: 0
Recent insider sentiment
Net selling — last 90 days
No buysSEK 8,900,000.00 sold
Share-award batches are excluded from this read — they’re compensation, not conviction.
0
Open-market buys (90d)
2
Sales (90d)
0
Share awards (90d)
2
Active insiders (90d)
Transactions
| Date | Person | Nature | Volume | Price | Value | Source |
|---|---|---|---|---|---|---|
| 02.09.2026 | Thomas Jonassen — Management | SoldDisposal via TJ Biotech Holding Aps | 350,000 | SEK 17.80 | SEK 6,230,000.00 | ↗ |
| 02.09.2026 | Jeppe Øvlesen — CEO | SoldDisposal via Quantass ApS | 150,000 | SEK 17.80 | SEK 2,670,000.00 | ↗ |
| 10.03.2026✎ | Anders Kronborg — Board member | Bought — open marketAcquisition | 2,750 | SEK 18.12 | SEK 49,830.00 | ↗ |
| 05.03.2026 | Mads Liebach Bjerregaard — Management | Bought — open marketAcquisition | 1,500 | SEK 17.92 | SEK 26,880.00 | ↗ |
| 05.03.2026 | Jeppe Øvli Øvlesen — CEO | Bought — open marketAcquisition via Quantass ApS | 7,900 | SEK 17.99 | SEK 142,145.58 | ↗ |
| 03.03.2026 | Thomas Boesen — Management | Bought — open marketAcquisition via Boesen Biotech ApS | 2,750 | SEK 17.92 | SEK 49,280.00 | ↗ |
| 03.03.2026 | Thomas Boesen — Management | Bought — open marketAcquisition via Boesen Biotech ApS | 2,700 | SEK 17.90 | SEK 48,330.00 | ↗ |
| 19.12.2025 | Thomas Jonassen — Management | Bought — open marketAcquisition via TJ Biotech Holding Aps | 3,529 | SEK 20.45 | SEK 72,168.05 | ↗ |
| 19.12.2025 | Anders Kronborg — Board member | Bought — open marketAcquisition | 3,470 | SEK 20.84 | SEK 72,301.27 | ↗ |
| 17.12.2025 | Quantass ApS — CEO | Bought — open marketAcquisition | 3,529 | SEK 20.24 | SEK 71,429.32 | ↗ |
Active insiders (90d)
Thomas Jonassen
Management
350,000 shares
1 filing
150,000 shares
1 filing